Bristol-Myers Squibb (NYSE:BMY) - Cours de l'action, nouvelles et analyse

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

BMY Aperçu des actions

Bristol-Myers Squibb Company découvre, développe, concède sous licence, fabrique, commercialise, distribue et vend des produits biopharmaceutiques dans le monde entier.

A propos de l'entreprise

BMY analyse fondamentale
Score flocon de neige
Évaluation	5/6
Croissance future	4/6
Performances passées	0/6
Santé financière	3/6
Dividendes	5/6

Récompenses

Se négocie à 67.6% en dessous de notre estimation de sa juste valeur

Les bénéfices devraient augmenter 45.95% par an

Se négocie à un bon prix par rapport à ses pairs et au secteur

Analyse des risques

A un niveau d'endettement élevé

Le dividende de 4.87% n'est pas bien couvert par les bénéfices

Community Narratives

Narratives bring a range of perspectives from our community.

WarrenAI

Based on Analyst Price Targets

Tactical Moves Steer Company Towards Robust Growth And Margin Expansion

US$51.69

6.9% undervalued

-1.32%

Revenue growth p.a.

about 1 month ago

Bristol-Myers Squibb Company Concurrents

Zoetis

NYSE:ZTS

US$82.0b

Pfizer

NYSE:PFE

US$163.8b

Merck

NYSE:MRK

US$295.6b

Johnson & Johnson

NYSE:JNJ

US$395.1b

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Bristol-Myers Squibb
Historique des cours de bourse
Prix actuel de l'action	US$48.11
Plus haut sur 52 semaines	US$63.41
Plus bas sur 52 semaines	US$39.35
Bêta	0.44
1Variation sur 1 mois	-4.64%
Variation sur 3 mois	16.66%
Variation sur 1 an	-22.50%
3Variation sur 3 ans	-27.76%
Variation sur 5 ans	0.083%
Évolution depuis l'introduction en bourse	2,151.58%

Nouvelles et mises à jour récentes

Bristol-Myers Squibb Company's (NYSE:BMY) Share Price Is Matching Sentiment Around Its Revenues

Aug 15

Bristol-Myers Squibb: A Potential Comeback In Healthcare

Aug 06

Bristol-Myers Squibb: Q2 Earnings Look Like An Inflection Point

Jul 27

Recent updates

Bristol-Myers Squibb Company's (NYSE:BMY) Share Price Is Matching Sentiment Around Its Revenues

Aug 15

Bristol-Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity

May 23

Bristol-Myers Squibb: A Lost Decade?

May 03

Lacklustre Performance Is Driving Bristol-Myers Squibb Company's (NYSE:BMY) Low P/S

Apr 29

Is Bristol Myers Squibb A Buy At These Bottom Levels?

Apr 22

Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)

Apr 12

Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis)

Apr 02

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

Mar 21

Bristol-Myers Squibb Is Not A Buy For Me

Mar 19

Bristol-Myers Squibb: Compelling Value From The New Products Portfolio And 4.5% Yield

Mar 07

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

Mar 07

We Think Bristol-Myers Squibb's (NYSE:BMY) Healthy Earnings Might Be Conservative

Feb 20

Bristol-Myers Squibb Company (NYSE:BMY) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Feb 06

Bristol-Myers Squibb: Massive Discount Spells Opportunity

Feb 04

BMY: Might Be Approaching A Bottom In 2024

Jan 23

Rendement pour les actionnaires

	BMY	US Pharmaceuticals	US Marché
7D	-2.5%	2.5%	1.6%
1Y	-22.5%	18.4%	26.3%

Rendement vs Industrie: BMY a sous-performé le secteur US Pharmaceuticals qui a rapporté 16 % au cours de l'année écoulée.

Rendement vs marché: BMY a sous-performé le marché US qui a rapporté 25.6 % au cours de l'année écoulée.

Volatilité des prix

Is BMY's price volatile compared to industry and market?
BMY volatility
BMY Average Weekly Movement	4.9%
Pharmaceuticals Industry Average Movement	10.5%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.2%
10% least volatile stocks in US Market	3.2%

Cours de l'action stable: BMY n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de BMY ( 5% ) est restée stable au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
1887	34,100	Chris Boerner	www.bms.com

Bristol-Myers Squibb Company découvre, développe, concède sous licence, fabrique, commercialise, distribue et vend des produits biopharmaceutiques dans le monde entier. Elle propose des produits pour l'hématologie, l'oncologie, les maladies cardiovasculaires, l'immunologie, la fibrose et les neurosciences. Les produits de la société comprennent Eliquis pour la réduction du risque d'accident vasculaire cérébral/embolie systémique en cas de fibrillation auriculaire non valvulaire, et pour le traitement de la TVP/de l'EP ; Opdivo pour diverses indications anticancéreuses, y compris la vessie, le sang, le CCR, la tête et le cou, le RCC, le HCC, le poumon, le mélanome, le MPM, l'estomac et le cancer de l'œsophage ; Pomalyst/Imnovid pour le myélome multiple ; Orencia pour la polyarthrite rhumatoïde active et l'arthrite psoriasique ; et Sprycel pour le traitement de la leucémie myéloïde chronique à chromosome Philadelphie positif.

Bristol-Myers Squibb Company Résumé des fondamentaux

Comment les bénéfices et les revenus de Bristol-Myers Squibb se comparent-ils à sa capitalisation boursière ?
BMY statistiques fondamentales
Capitalisation boursière	US$97.54b
Bénéfices(TTM)	-US$6.54b
Recettes(TTM)	US$46.51b

2.1x

Ratio P/S

-14.9x

Ratio P/E

Le site BMY est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
BMY compte de résultat (TTM)
Recettes	US$46.51b
Coût des recettes	US$11.08b
Marge brute	US$35.43b
Autres dépenses	US$41.97b
Les revenus	-US$6.54b

Derniers bénéfices déclarés

Jun 30, 2024

Prochaine date de publication des résultats

Oct 31, 2024

Résultat par action (EPS)	-3.23
Marge brute	76.18%
Marge bénéficiaire nette	-14.06%
Ratio dettes/capitaux propres	306.9%

Quelles ont été les performances à long terme de BMY?

Voir les performances historiques et les comparaisons

Dividendes

5.0%

Rendement actuel des dividendes

-74%

Ratio de distribution

BMY Aperçu des actions

Récompenses

Analyse des risques

Tactical Moves Steer Company Towards Robust Growth And Margin Expansion

Bristol-Myers Squibb Company Concurrents

NYSE:ZTS

US$82.0b

NYSE:PFE

US$163.8b

NYSE:MRK

US$295.6b

NYSE:JNJ

US$395.1b

Historique des prix et performances

Nouvelles et mises à jour récentes

Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma

European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

Bristol-Myers Squibb Company's (NYSE:BMY) Share Price Is Matching Sentiment Around Its Revenues

Bristol-Myers Squibb: A Potential Comeback In Healthcare

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bristol-Myers Squibb: Q2 Earnings Look Like An Inflection Point

Recent updates

Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma

European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

Bristol-Myers Squibb Company's (NYSE:BMY) Share Price Is Matching Sentiment Around Its Revenues

Bristol-Myers Squibb: A Potential Comeback In Healthcare

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bristol-Myers Squibb: Q2 Earnings Look Like An Inflection Point

Consensus EPS estimates fall by 18%

Bristol-Myers Squibb Company Announces Intangible Asset Impairment Charges for the Three Months Ended June 30, 2024

Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma

Bristol Myers Squibb: The More It Drops, The More I Buy

Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

Bristol-Myers Squibb Company to Report Q2, 2024 Results on Jul 26, 2024

First quarter dividend of US$0.60 announced

Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024

Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024

Is Bristol-Myers Squibb (NYSE:BMY) A Risky Investment?

Bristol Myers: Quality Fundamentals Suppressed By Interest Rates

Bristol Myers Squibb Announces Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carinoma in Checkmate -9DW Trial

Bristol Myers Squibb’S Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented At 2024 Asco® Annual Meeting

Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine

Bristol-Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity

Bristol Myers Squibb Announces New Four-Year Results from the POETYK PSO Long-Term Extension Trial of Sotyktu (Deucravacitinib) Treatment in Adult Patients with Moderate-To-Severe Plaque Psoriasis

Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approves by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma

Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)

European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

Bristol-Myers Squibb: A Lost Decade?

Lacklustre Performance Is Driving Bristol-Myers Squibb Company's (NYSE:BMY) Low P/S

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Bristol Myers Squibb A Buy At These Bottom Levels?

Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)

Consensus EPS estimates fall by 24%

Bristol Myers Squibb Announces KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio’S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

European Commission Expands Approval of Bristol Myers Squibb’S Reblozyl® (Luspatercept)

Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis)

Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (Oozanimod) in Patients with Moderate to Severe Active Crohn's Disease

Upcoming dividend of US$0.60 per share

Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024

Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

Bristol-Myers Squibb Company, Annual General Meeting, May 07, 2024

Bristol-Myers Squibb Is Not A Buy For Me

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Karuna Therapeutics, Inc. (NasdaqGM:KRTX) from Capital International Investors, FMR LLC, The Vanguard Group, Inc., T. Rowe Price Group, Inc. (NasdaqGS:TROW) and others.

FDA Advisory Committee Votes in Favor of Bristol-Myers Squibb Company and 2seventy bio, Inc. Abecma for Triple-Class Exposed Multiple Myeloma in Further Lines of Therapy

U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Executive Chairman of the Board exercised options and sold US$3.6m worth of stock

Bristol-Myers Squibb Company to Report Q1, 2024 Results on Apr 25, 2024

U.S. Food and Drug Administration Approves Bristol-Myers Squibb Company's Opdivo

Bristol-Myers Squibb: Compelling Value From The New Products Portfolio And 4.5% Yield

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

Fourth quarter dividend of US$0.60 announced

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of RayzeBio, Inc. (NasdaqGM:RYZB).

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of RayzeBio, Inc. (NasdaqGM:RYZB).

Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)